Sintetica SA   Report issue

For profit Phase 2 Phase 3
Founded: Mendrisio Switzerland (1921)

Organization Overview

First Clinical Trial
2015
NCT02385097
First Marketed Drug
2019
phenylephrine (Prefrin)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Sintetica SA | SINTETICA SA | SINTETICA, SA | SINTETICA US | Vissum Alicante, Calle del Cabañal 1, 03016 Alicante, Spain

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Flatfoot (Phase 2)

Hernia (Phase 2)

Hernia, Inguinal (Phase 2)

Pain, Postoperative (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8